A targeted combination of azacitidine and trametinib produced a rapid reduction in diffuse leptomeningeal thickening in an infant with congenital melanocytic nevus syndrome and neurocutaneous melanosis, according to a case report with follow-up to 53 months. Teams used ventriculoperitoneal shunting for intracranial pressure and molecular profiling confirmed an activating NRAS p.Gln61Lys variant with an allele frequency of 35 percent. The report highlights a rare but high-impact pathway for disease modification in a condition with historically poor neurological prognosis once symptoms emerge.
Get the Daily Brief